Table 2.
Multivariate analysis of hematopoietic engraftment, and GVHD.
| Neutrophil engraftment | Platelet engraftment | Grades II–IV aGVHD | Grades III–IV aGVHD | cGVHD | Extensive cGVHD | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | ||
| Donor | |||||||||||||
| MSD | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| 8/8MUD | 0.62 (0.52–0.74) | <0.001 | 0.67 (0.53–0.84) | <0.001 | 1.14 (0.85–1.51) | 0.360 | 1.08 (0.66–1.75) | 0.750 | 0.86 (0.66–1.12) | 0.290 | 0.84 (0.59–1.19) | 0.340 | |
| 7/8MUD | 0.50 (0.41–0.60) | <0.001 | 0.54 (0.42–0.69) | <0.001 | 1.45 (1.06–1.97) | 0.018 | 1.08 (0.62–1.89) | 0.770 | 0.84 (0.90–1.13) | 0.270 | 0.79 (0.53–1.18) | 0.270 | |
| UCB | 0.31 (0.26–0.37) | <0.001 | 0.31 (0.24–0.38) | <0.001 | 1.44 (1.08–1.91) | 0.012 | 1.36 (0.84–2.20) | 0.200 | 0.45 (0.33–0.60) | <0.001 | 0.40 (0.26–0.60) | <0.001 | |
| Recipient age | |||||||||||||
| 50–59 years | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| ≥ 60 years | 1.03 (0.93–1.15) | 0.470 | 1.03 (0.91–1.16) | 0.590 | 0.84 (0.71–0.99) | 0.040 | 0.84 (0.63–1.13) | 0.260 | 0.97 (0.80–1.17) | 0.800 | 1.01 (0.78–1.31) | 0.900 | |
| Recipient sex | |||||||||||||
| Female | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Male | 0.91 (0.82–1.01) | 0.091 | 0.80 (0.71–0.90) | <0.001 | 1.03 (0.87–1.22) | 0.730 | 0.97 (0.73–1.30) | 0.870 | 1.11 (0.91–1.34) | 0.290 | 1.26 (0.96–1.65) | 0.087 | |
| PS | |||||||||||||
| 0–1 | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| 2–4 | 0.83 (0.68–1.02) | 0.079 | 0.61 (0.48–0.78) | <0.001 | 0.99 (0.73–1.35) | 1.000 | 1.07 (0.65–1.77) | 0.770 | 0.76 (0.52–1.13) | 0.180 | 1.03 (0.64–1.65) | 0.880 | |
| HCT–CI | |||||||||||||
| 0–2 | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| ≥3 | 0.92 (0.83–1.03) | 0.180 | 0.83 (0.73–0.94) | 0.004 | 0.88 (0.73–1.06) | 0.180 | 0.99 (0.72–1.37) | 0.990 | 0.89 (0.72–1.10) | 0.280 | 0.88 (0.66–1.18) | 0.410 | |
| Karyotype | |||||||||||||
| Others | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Poor | 1.02 (0.92–1.12) | 0.670 | 1.01 (0.90–1.13) | 0.800 | 1.04 (0.89–1.22) | 0.580 | 0.85 (0.65–1.13) | 0.280 | 0.91 (0.76–1.09) | 0.350 | 0.90 (0.70–1.16) | 0.440 | |
| Disease risk at HCT | |||||||||||||
| Low-risk | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| High-risk | 0.98 (0.89–1.09) | 0.820 | 0.99 (0.88–1.11) | 0.880 | 1.01 (0.85–1.20) | 0.860 | 1.02 (0.76–1.36) | 0.870 | 0.93 (0.77–1.12) | 0.460 | 0.88 (0.68–1.13) | 0.320 | |
| Conditioning regimen | |||||||||||||
| MAC | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| RIC | 1.07 (0.97–1.19) | 0.160 | 1.10 (0.98–1.23) | 0.080 | 0.90 (0.76–1.06) | 0.220 | 0.79 (0.58–1.05) | 0.110 | 0.81 (0.67–0.98) | 0.033 | 0.81 (0.63–1.06) | 0.130 | |
| GVHD prophylaxis | |||||||||||||
| With MTX | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Without MTX | 1.22 (1.06–1.40) | 0.003 | 1.00 (0.87–1.16) | 0.900 | 0.99 (0.81–1.22) | 0.970 | 1.06 (0.75–1.50) | 0.710 | 1.19 (0.93–1.54) | 0.160 | 1.04 (0.72–1.52) | 0.800 | |
| Use of ATG | |||||||||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference | |||||||
| Yes | 1.46 (1.22–1.74) | <0.001 | 1.35 (1.12–1.63) | 0.001 | 0.79 (0.59–1.04) | 0.100 | 0.42 (0.21–0.82) | 0.011 | 0.83 (0.61–1.13) | 0.240 | 0.79 (0.51–1.21) | 0.280 | |
GVHD graft-versus-host disease, MSD matched sibling donor, MUD matched unrelated donor, UCB unrelated cord blood, PS performance status, HCT-CI hematopoietic cell transplantation-specific comorbidity index, HCT hematopoietic cell transplantation, MAC myeloablative conditioning, RIC reduced-intensity conditioning, GVHD graft-versus-host disease, MTX methotrexate, ATG antithymocyte globulin, HR hazard ratio, CI confidence interval. The P values in bold are statistically significant (<0.05).